- Home
- ESLA vs SRTS Comparison
ESLA vs SRTS Comparison
Compare ESLA & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | SRTS |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 65.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ESLA | SRTS |
|---|---|---|
| Price | $1.82 | $4.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.00 | $6.67 |
| AVG Volume (30 Days) | ★ 80.5K | 39.3K |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $3.03 |
| 52 Week High | $3.15 | $5.92 |
Technical Indicators
Market Signals| Indicator | ESLA | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 80.61 | 54.65 |
| Support Level | $1.48 | $3.66 |
| Resistance Level | $2.22 | $4.80 |
| Average True Range (ATR) | 0.15 | 0.27 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 85.71 | 65.84 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.